EICHORPublic-registry trials using Risankizumab that Eichor's radar has found — 1 trial. All data below is from public sources; Eichor is not affiliated with any sponsor.
Risankizumab appears in 1 registered trial Eichor's radar has found, sponsored by AbbVie, the most recent registered as Phase 2, with a planned enrollment of 2,000. Registered timeline: 2026–2031. The registry holds 2,063 registered studies for Crohn's Disease.
| Trial | Sponsor | Condition | Phase | Sites |
| Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis | AbbVie | Crohn's Disease | PHASE2 | 30 |
| Status | Not Yet Recruiting · planned start 2026-07 |
| Primary completion | 2031-10 |
| Enrollment target | 2,000 participants |
| Design | Randomized · Parallel · Phase 2 · 22 arms |
| Who it enrolls | All sexes · 18 Years and older — full criteria are on the study record |
| Locations | 30 listed in Australia, Belgium, Germany, Japan |
All fields verbatim from the ClinicalTrials.gov record for NCT07697456.
| First FDA approval | SKYRIZI — April 2019 (application BLA761105, currently held by ABBVIE INC) |
| Also known as | SKYRIZI |
| Approved applications | 2 |
| Forms & routes | Injectable · Injection, Intravenous |
| Registry-wide use | 119 registered studies all-time · 30 currently recruiting |
Sources: FDA Drugs@FDA and ClinicalTrials.gov, public records. The application holder shown is the current holder, which may differ from the original developer.
The public registry holds 2,063 registered studies for Crohn's Disease. Compounds appearing across the 200 most recently updated registry entries:
Eichor generates a preliminary site-risk snapshot — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Trialed alongside
Other Crohn's Disease drugs
← Eichor home · All tracked trials · Crohn's Disease studies · Weekly briefs
